Natalizumab: A new treatment for relapsing remitting multiple sclerosis
Therapeutics and Clinical Risk Management · 2007-04 · 3 (2) · 259-268
DOI: 10.2147/tcrm.2007.3.2.259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutics and Clinical Risk Management, 2007-04. Verfasst von Michael Hutchinson. Beteiligte Einrichtung: Department of Neurology, St. Vincent’s University Hospital, Dublin Ireland. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Neurology, St. Vincent’s University Hospital, Dublin Ireland.
Zitieren
APA
Hutchinson, M. (2007). Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Therapeutics and Clinical Risk Management, 3(2), 259-268. https://doi.org/10.2147/tcrm.2007.3.2.259
Vancouver
Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Therapeutics and Clinical Risk Management. 2007;3(2):259-268. doi:10.2147/tcrm.2007.3.2.259
BibTeX
@article{Hutchinson2007,
author = {Hutchinson, Michael},
title = {Natalizumab: A new treatment for relapsing remitting multiple sclerosis},
journal = {Therapeutics and Clinical Risk Management},
year = {2007},
volume = {3},
number = {2},
pages = {259--268},
doi = {10.2147/tcrm.2007.3.2.259}
}
EUVIMED